ClinicalTrials.gg
CompletedNCT03066804PARALLAXUpdated Oct 11, 2021Results posted

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

A Phase 3 interventional study of sacubitril/valsartan and Enalapril in Heart Failure With Preserved Ejection Fraction, sponsored by Novartis Pharmaceuticals. Completed at 381 sites in 32 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.

Primary conditionHeart FailureRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure
Why
  1. The study's listed conditions name Heart Failure, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,572
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing sacubitril in Heart Failure — 5 open to participants now, 5 under way, 2 of them phase 3. sacubitril · Heart Failure.

Enrollment
Largest of 24
2,572 · median 104
Started
2017
with 2 others
Phase 3
7 of 24
2 open now
Registered
4th of 24
by date
Lead sponsor
5 of 24
Novartis Pharmaceuticals

Among the 24 studies testing sacubitril in Heart Failure, this one has the largest enrollment, is one of 3 that started in 2017, is one of 7 in phase 3, and was the 4th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 24 studies testing sacubitril in Heart Failure are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About sacubitril

sacubitril: first FDA approval 2015 (ENTRESTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing sacubitril in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).

Read the detailed description

This study was a 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate sacubitril/valsartan compared to individualized medical therapy on NT proBNP, exercise capacity, symptoms and QoL in patients with heart failure and preserved left ventricular ejection (HFpEF) fraction (LVEF > 40%). Patients were initially stratified into one of three strata according to prior treatment for comorbidities: Angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or no prior renin angiotensin system inhibitors (RASi). Patients in each stratum were randomized in a 1:1 ratio and received either sacubitril/valsartan or comparator (i.e.

enalapril for patients in ACEi strata, valsartan for patients in the ARB strata and placebo for patients in the No RASi strata). There was no designated proportion of patients planned in each stratum; the strata were populated based upon the patient's prior treatment regimen. The study consisted of a screening epoch of up to 2 weeks and a randomized treatment epoch of 24 weeks, which included a 1 to 4 week study drug up-titration epoch followed by a 20 to 23 week maintenance epoch. Uptitration to target doses was recommended to occur within the first four weeks of the study, and was performed by Investigator's discretion based on the patient's clinical status.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

Keywords

  • Cardiovascular Diseases
  • Heart Failure
  • Heart failure with Preserved Ejection Fraction
  • NT-proBNP
  • 6 MWT
  • KCCQ
  • SF-36
  • NYHA Class
  • LCZ696
  • Enalapril
  • Valsartan
  • Angiotensin-Converting Enzyme Inhibitors (ACEi)
  • Angiotensin II Type 1 Receptor Blockers (ARB)
  • Renin Angiotensin System Inhibitors (RASi)
04

In context

Heart Failure Reclassified

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

This study's enrollment of 2,572 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (LVEF) >40% by echo within 6 months prior to study entry or during the screening epoch
  • Symptom(s) of heart failure (HF) requiring treatment with diuretics (including loop, or thiazide diuretics, or mineralocorticoid antagonist [MRAs]) for at least 30 days prior to study entry
  • class II-IV
  • Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram.
  • NT-proBNP > 220 pg/mL for patients with no atrial fibrillation/atrial flutter (AF) or >600 pg/mL for patients with AF
  • KCCQ clinical summary score \< 75
  • Patients on ACEi or ARB therapy must have a history of HTN

Exclusion criteria

Exclusion Criteria:

  • Any prior measurement of ≤ 40%, under stable conditions
  • Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months , or urgent percutaneous coronary intervention (PCI) within 3 months or an elective PCI within 30 days prior to study entry
  • Any clinical event within the 6 months prior to Visit 1 that could have reduced the LVEF (eg MI, coronary artery bypass graft [CABG]), unless an echo measurement was performed after the event confirming the LVEF to be >40%
  • Current (within 30 days from Visit 1) acute decompensated HF requiring therapy.
  • Current (within 30 days from Visit 1) use of renin inhibitor(s), dual RAS blockade or LCZ696
  • History of to LCZ696 or its components
  • Patients with a known history of angioedema
  • Walk distance primarily limited by non-cardiac comorbid conditions at study entry
  • Alternative reason for shortness of breath such as: significant pulmonary disease or severe , (Hgb) \<10 g/dL males and \< 9.5 g/dL females, or (BMI) > 40 kg/m\^2.
  • Systolic blood pressure (SBP) ≥ 180 mmHg at study entry, or SBP >150 mmHg and \<180 mmHg at study entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP \< 110 mmHg at study entry.
  • Patients with > 7.5% not treated for diabetes
  • Patients with prior major organ transplant or intent to transplant (ie on transplant list)
  • \< 30 ml/min/1.73 m\^2 as measured by MDRD at screening
  • Serum potassium > 5.2 mmol /L (or equivalent plasma potassium value) at study entry
  • History or presence of any other disease with a of \< 3 years
  • Pregnant or nursing women or women of unless they are using highly effective methods of

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,572 participants (actual)

Study arms

  • Experimental
    sacubitril/valsartan (LCZ696)

    All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo. Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo). In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally).

    Drug: sacubitril/valsartan · Drug: Placebo to match enalapril · Drug: Placebo to match valsartan

  • Active comparator
    Comparator

    Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum). Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily). Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily). Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo.

    Drug: Enalapril · Drug: Valsartan · Drug: Placebo to match sacubitril/valsartan

Interventions

  • Drugsacubitril/valsartan

    Drug pages: Sacubitril · Valsartan

    Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally

  • Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally

  • Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally

  • DrugPlacebo to match sacubitril/valsartan

    Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally

  • DrugPlacebo to match enalapril

    Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally

  • DrugPlacebo to match valsartan

    Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally

07

What researchers measure

Primary outcomes

  1. Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12

    To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF

    Time frame: Baseline, week 12

  2. Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24

    Change from baseline in 6-minute walk distance (6MWD) will be reported at Week 24. The 6 MWT will be performed in accordance with the guidelines of the American Thoracic Society 2002.

    Time frame: Baseline, week 24

Secondary outcomes

  1. Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24

    The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.

    Time frame: Baseline, Week 24

  2. Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24

    Percentage of patients with KCCQ CSS deterioration ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.

    Time frame: Baseline, Week 24

  3. Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24

    Percentage of patients with KCCQ CSS improvement ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.

    Time frame: Baseline, Week 24

  4. Change From Baseline in NYHA Functional Class at Week 24

    NYHA classification is a subjective physician's assessment of patient's functional capacity and symptomatic status and can change frequently over time. Class I - No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF Class II - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF Class III - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF Class IV - Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest The NYHA class change will be analyzed as a three category ordinal variable with levels: "improved", "unchanged", and "worsened", defined by at least one class improvement, no change, at least one class worsening, in NYHA class, respectively.

    Time frame: Baseline, week 24

  5. Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

    The SF-36 PCS score reflects the measure of quality of life based on the 36 questions which evaluate the person's physical, emotional, and mental status, including general health. Specifically, the SF-36 PCS score focuses on assessing the person's physical status. The score ranges from 0 to 100 with a higher score indicating a better status of physical wellbeing (range = 0 "worst"-100 "best").

    Time frame: Baseline, Week 24

08

Results

Posted Feb 8, 2021

Participant flow

A total of 2572 participants were randomized in a 1:1 ratio to receive either sacubitril/valsartan or Individualized Medical Therapy (IMT).

Participant flow — Overall Study
MilestoneSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) Comparator
Started12861286
Completed12351236
Not completed5150
Withdrew: Physician decision04
Withdrew: Death2317
Withdrew: Withdrawal by subject1925
Withdrew: Lost to follow-up20
Withdrew: Adverse event23
Withdrew: Technical problems51

Outcome measures

PrimaryChange From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12

To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF

Time frame:
Baseline, week 12
Reported as:
Geometric mean · Ratio
Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12
RatioSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) Comparator
Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 120.8218 (0.7955 to 0.8489)0.9828 (0.9515 to 1.0151)
Statistical analysis
  • Sacubitril/Valsartan (LCZ696) vs Individualized Medical Therapy (IMT) Comparator · Mixed Models Analysis · p = <0.0001 · Geometric mean ratio: 0.8362 · 95% CI 0.7987 to 0.8754
PrimaryChange From Baseline in 6 Minute Walk Distance (6MWD) at Week 24

Change from baseline in 6-minute walk distance (6MWD) will be reported at Week 24. The 6 MWT will be performed in accordance with the guidelines of the American Thoracic Society 2002.

Time frame:
Baseline, week 24
Reported as:
Mean · Meters
Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24
MetersSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) Comparator
Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 249.6935 (5.4310 to 13.9559)12.1920 (7.9202 to 16.4638)
Statistical analysis
  • Sacubitril/Valsartan (LCZ696) vs Individualized Medical Therapy (IMT) Comparator · Mixed Models Analysis · p = 0.4164 · Mean difference (net): -2.4985 · 95% CI -8.5267 to 3.52297
SecondaryMean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24

The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.

Time frame:
Baseline, Week 24
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24
Scores on a scaleSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) Comparator
Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 2412.3399 (11.3151 to 13.3647)11.8168 (10.7922 to 12.8415)
Statistical analysis
  • Sacubitril/Valsartan (LCZ696) vs Individualized Medical Therapy (IMT) Comparator · Mixed Models Analysis · p = 0.4791 · Mean difference (net): 0.5231 · 95% CI -0.9258 to 1.9720
SecondaryPercentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24

Percentage of patients with KCCQ CSS deterioration ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24
Percentage of participantsSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) Comparator
Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 2415.4916.69
Statistical analysis
  • Sacubitril/Valsartan (LCZ696) vs Individualized Medical Therapy (IMT) Comparator · longitudinal binary logistic regression · p = 0.5294 · Odds ratio (or): 0.8993 · 95% CI 0.6461 to 1.2518
SecondaryPercentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24

Percentage of patients with KCCQ CSS improvement ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24
Percentage of participantsSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) Comparator
Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 2467.9465.70
Statistical analysis
  • Sacubitril/Valsartan (LCZ696) vs Individualized Medical Therapy (IMT) Comparator · longitudinal binary logistic regression · p = 0.4938 · Odds ratio (or): 1.1060 · 95% CI 0.8287 to 1.4760
SecondaryChange From Baseline in NYHA Functional Class at Week 24

NYHA classification is a subjective physician's assessment of patient's functional capacity and symptomatic status and can change frequently over time. Class I - No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF Class II - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF Class III - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF Class IV - Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest The NYHA class change will be analyzed as a three category ordinal variable with levels: "improved", "unchanged", and "worsened", defined by at least one class improvement, no change, at least one class worsening, in NYHA class, respectively.

Time frame:
Baseline, week 24
Reported as:
Number · Percentage of Participants
Change From Baseline in NYHA Functional Class at Week 24
Percentage of ParticipantsSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) Comparator
Improved23.6224.00
Unchanged72.2371.68
Worsened4.154.31
Statistical analysis
  • Sacubitril/Valsartan (LCZ696) vs Individualized Medical Therapy (IMT) Comparator · Proportional cumulative odds model · p = 0.8314 · Odds ratio (or): 0.9798 · 95% CI 0.8122 to 1.1820
SecondaryChange From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

The SF-36 PCS score reflects the measure of quality of life based on the 36 questions which evaluate the person's physical, emotional, and mental status, including general health. Specifically, the SF-36 PCS score focuses on assessing the person's physical status. The score ranges from 0 to 100 with a higher score indicating a better status of physical wellbeing (range = 0 "worst"-100 "best").

Time frame:
Baseline, Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
Scores on a scaleSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) Comparator
Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 242.5405 (2.0787 to 3.0023)2.6975 (2.2360 to 3.1590)
Statistical analysis
  • Sacubitril/Valsartan (LCZ696) vs Individualized Medical Therapy (IMT) Comparator · Mixed Models Analysis · p = 0.6370 · Mean difference (net): -0.1570 · 95% CI -0.8093 to 0.4953

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approx. 2 years.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sacubitril/Valsartan (LCZ696)23/1,280 (1.8%)186/1,280 (14.5%)964/1,280 (75.3%)
Individualized Medical Therapy (IMT)17/1,284 (1.3%)191/1,284 (14.9%)832/1,284 (64.8%)
Total40/2,564 (1.6%)377/2,564 (14.7%)1,796/2,564 (70%)
Most frequent serious events
Showing 10 of 250
Most frequent serious events
EventSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT)Total
Cardiac failureCardiac disorders21/128031/128452/2564
Atrial fibrillationCardiac disorders13/128017/128430/2564
PneumoniaInfections and infestations13/128013/128426/2564
Cardiac failure acuteCardiac disorders3/12809/128412/2564
Angina pectorisCardiac disorders8/12808/128416/2564
Angina unstableCardiac disorders6/12807/128413/2564
Cardiac failure congestiveCardiac disorders2/12807/12849/2564
Acute kidney injuryRenal and urinary disorders4/12807/128411/2564
HypotensionVascular disorders6/12802/12848/2564
Ischaemic strokeNervous system disorders0/12806/12846/2564
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT)Total
HypotensionVascular disorders176/128069/1284245/2564
Urine albumin/creatinine ratio increasedInvestigations157/128097/1284254/2564
Glomerular filtration rate decreasedInvestigations137/1280150/1284287/2564
HyperkalaemiaMetabolism and nutrition disorders148/1280138/1284286/2564
Renal impairmentRenal and urinary disorders148/1280110/1284258/2564
HaematuriaRenal and urinary disorders145/1280104/1284249/2564
ProteinuriaRenal and urinary disorders121/128084/1284205/2564
HypertensionVascular disorders42/128081/1284123/2564
DizzinessNervous system disorders70/128063/1284133/2564
Urine protein/creatinine ratio increasedInvestigations66/128065/1284131/2564

Baseline characteristics

The Full Analysis Set was the primary efficacy population used in the analyses for all efficacy endpoints and included all randomized patients except 6 patients (5 in sacubitril/valsartan group and 1 in IMT group) excluded due to misrandomization or misstratification.

Age, Customized
Age, Customized(Participants)Sacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) ComparatorTotal
<65 years196221417
>=65 years108510642149
Sex: Female, Male
Sex: Female, Male(Participants)Sacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) ComparatorTotal
Female6436581301
Male6386271265
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sacubitril/Valsartan (LCZ696)Individualized Medical Therapy (IMT) ComparatorTotal
Caucasian111211172229
Black111627
Asian5659115
Native American393372
Pacific Islander011
Unknown437
Other5956115
09

Study locations

381 sites
  • Novartis Investigative Site
    Andalusia, Alabama 36420, United States
  • Novartis Investigative Site
    Mobile, Alabama 36608, United States
  • Novartis Investigative Site
    Beverly Hills, California 90211, United States
  • Novartis Investigative Site
    Long Beach, California 90813, United States
  • Novartis Investigative Site
    Santa Ana, California 92704, United States
  • Novartis Investigative Site
    Sylmar, California 91342, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Stamford, Connecticut 06905, United States
  • Novartis Investigative Site
    Bradenton, Florida 34209, United States
  • Novartis Investigative Site
    Gainesville, Florida 32608, United States
  • Novartis Investigative Site
    Hollywood, Florida 33312, United States
  • Novartis Investigative Site
    Miami, Florida 33133, United States
  • Novartis Investigative Site
    Port Orange, Florida 32127, United States
  • Novartis Investigative Site
    Thomasville, Georgia 31792, United States
  • Novartis Investigative Site
    Arlington Heights, Illinois 60004, United States
  • Novartis Investigative Site
    Alexandria, Louisiana 71301, United States
  • Novartis Investigative Site
    Chalmette, Louisiana 70043, United States
  • Novartis Investigative Site
    Houma, Louisiana 70360, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Lincoln, Nebraska 68526, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68114, United States
  • Novartis Investigative Site
    Rochester, New York 14621, United States
  • Novartis Investigative Site
    Marion, Ohio 43302, United States
  • Novartis Investigative Site
    Corvallis, Oregon 97330, United States
  • Novartis Investigative Site
    Abington, Pennsylvania 19001, United States
  • Novartis Investigative Site
    Sioux Falls, South Dakota 57104, United States
  • Novartis Investigative Site
    Jackson, Tennessee 38301, United States
  • Novartis Investigative Site
    Dallas, Texas 75234, United States
  • Novartis Investigative Site
    Lufkin, Texas 75904, United States
  • Novartis Investigative Site
    Tomball, Texas 77375, United States
  • Novartis Investigative Site
    Falls Church, Virginia 22042, United States
  • Novartis Investigative Site
    Seattle, Washington 98122, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1280AEB, Argentina
  • Novartis Investigative Site
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Novartis Investigative Site
    Posadas, Misiones N3300AHX, Argentina
  • Novartis Investigative Site
    Ciudad de Salta, Provincia De Salta A4406BPF, Argentina
  • Novartis Investigative Site
    Tucuman, San Miguel De Tucuman T4000ICL, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000DSV, Argentina
  • Novartis Investigative Site
    San Miguel de Tucuman, Tucuman T4000IFL, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1430EGF, Argentina
  • Novartis Investigative Site
    Cordoba, X5000AAW, Argentina
  • Novartis Investigative Site
    Cordoba, X5000EVQ, Argentina
  • Novartis Investigative Site
    Cordoba, X5000, Argentina
  • Novartis Investigative Site
    Cordoba, X5004BAL, Argentina
  • Novartis Investigative Site
    Cordoba, X5006CBI, Argentina
  • Novartis Investigative Site
    Formosa, P3600, Argentina
  • Novartis Investigative Site
    San Luis, D5702JRS, Argentina
  • Novartis Investigative Site
    Santa Fe, 3080, Argentina
  • Novartis Investigative Site
    Santa Fe, S2200, Argentina
  • Novartis Investigative Site
    Santa Fe, S3000FWO, Argentina
  • Novartis Investigative Site
    Braunau, A5280, Austria
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative Site
    Hall in Tirol, 6060, Austria
  • Novartis Investigative Site
    Linz, 4010, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Genk, 3600, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Heusden-Zolder, 3550, Belgium
  • Novartis Investigative Site
    Huy, 4500, Belgium
  • Novartis Investigative Site
    Kortrijk, 8500, Belgium
  • Novartis Investigative Site
    Fortaleza, CE 60430 370, Brazil
  • Novartis Investigative Site
    Goiania, GO 74223-130, Brazil
  • Novartis Investigative Site
    Goiania, GO 74605 050, Brazil
  • Novartis Investigative Site
    Belo Horizonte, MG 30140 062, Brazil
  • Novartis Investigative Site
    Belo Horizonte, MG 30150-221, Brazil
  • Novartis Investigative Site
    Curitiba, Parana 80230 130, Brazil
  • Novartis Investigative Site
    Canoas, Rio Grande Do Sul 92425 900, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90880-480, Brazil
  • Novartis Investigative Site
    Blumenau, SC 89010 500, Brazil
  • Novartis Investigative Site
    Campinas, SP 13060 080, Brazil
  • Novartis Investigative Site
    Ribeirao Preto, SP 14048-900, Brazil
  • Novartis Investigative Site
    Sao Jose do Rio Preto, SP 15015-750, Brazil
  • Novartis Investigative Site
    Sao Jose do Rio Preto, SP 15090-000, Brazil
  • Novartis Investigative Site
    Burgas, 8018, Bulgaria
  • Novartis Investigative Site
    Pazardzhik, 4400, Bulgaria
  • Novartis Investigative Site
    Pernik, 2300, Bulgaria
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4000, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Shumen, 9700, Bulgaria
  • Novartis Investigative Site
    Sofia, 1233, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Sofia, 1527, Bulgaria
  • Novartis Investigative Site
    Sofia, 1606, Bulgaria
  • Novartis Investigative Site
    Veliko Tarnovo, 5000, Bulgaria
  • Novartis Investigative Site
    Moncton, New Brunswick E1G 1A7, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8L 2X2, Canada
  • Novartis Investigative Site
    Oakville, Ontario L6K 3W7, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 1C8, Canada
  • Novartis Investigative Site
    St-Georges Beauce, Quebec G5Y 4T8, Canada
  • Novartis Investigative Site
    Medellin, Antioquia 050036, Colombia
  • Novartis Investigative Site
    Cali, Valle Del Cauca 760001, Colombia
  • Novartis Investigative Site
    Barranquilla, 080020, Colombia
  • Novartis Investigative Site
    Barranquilla, Colombia
  • Novartis Investigative Site
    Monteria, Colombia
  • Novartis Investigative Site
    San Gil, 684031, Colombia
  • Novartis Investigative Site
    Brandys nad Labem, Czech Republic 250 01, Czechia
  • Novartis Investigative Site
    Brno, Czech Republic 60200, Czechia
  • Novartis Investigative Site
    Cesky Krumlov, Czech Republic 381 01, Czechia
  • Novartis Investigative Site
    Jablonec nad Nisou, Czech Republic 466 60, Czechia

Showing the first 100 of 381 sites across 32 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR; PARALLAX Investigators and Committee members. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021 Nov 16;326(19):1919-1929. doi: 10.1001/jama.2021.18463. PubMed 34783839 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Oct 2019, 26 months.

Results were first posted in Feb 2021, 1 year 3 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 26 months is below that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2017
First posted
Feb 28, 2017
StartActual
Aug 22, 2017
Primary completionActual
Oct 28, 2019
CompletionActual
Oct 28, 2019
Results first posted
Feb 8, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03066804
Responsible party
Sponsor
First posted
Feb 28, 2017
Start date
Aug 22, 2017
Primary completion
Oct 28, 2019
Completion
Oct 28, 2019
Results posted
Feb 8, 2021
Last update
Oct 11, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacubitril · Valsartan

Start the discussion